Skip to main content

Advertisement

SpringerLink
Log in

Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight

  • Mini Review
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

With recent advances in targeted therapy such as tyrosine kinase inhibitor (TKI) therapy for non-small cell lung cancer (NSCLC), pulmonary toxicity has emerged as a problem. The recognition of common CT findings and patterns of TKI-induced interstitial lung disease (ILD) is mandatory for achieving a timely diagnosis and for the appropriate management of this condition. Therefore, familiarity with this complicating ILD is crucial.

Methods

We reviewed all published literature in the English language regarding the ILD among NSCLC patients receiving TKIs.

Results

The previous reports focused on the incidence, mortality rate, and risk factors of TKI-induced ILDs. This review elaborates on the diverse CT findings and predominant patterns of ILDs associated with TKI therapy. Emphases will be given on the role of CT, in particular, for the diagnosis of the subacute or chronic appearance of ILDs. This review also offers information about the pathogenesis and risk factor for the development of TKI-induced ILD. Representative cases will be presented as a pictorial review.

Conclusions

It is important to recognize the various patterns of TKI-induced ILDs, which increase in incidence with the introduction of diverse types of molecularly targeted agents. Poor prognoses are expected when there is a short interval from the initiation of target therapy to the onset of ILD, acute interstitial pneumonia pattern of ILD, and preexisting pulmonary fibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957

    Article  PubMed  CAS  Google Scholar 

  2. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388

    Article  PubMed  CAS  Google Scholar 

  3. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361(9352):137–139

    Article  PubMed  Google Scholar 

  4. Makris D, Scherpereel A, Copin M, Colin G, Brun L, Lafitte J, Marquette C (2007) Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC cancer 7(1):150

    Article  PubMed  Google Scholar 

  5. Liu V, White D, Zakowski M, Travis W, Kris M, Ginsberg M, Miller V, Azzoli C (2007) Pulmonary toxicity associated with Erlotinib*. Chest 132(3):1042–1044

    Article  PubMed  Google Scholar 

  6. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24(16):2549–2556

    Article  PubMed  CAS  Google Scholar 

  7. Hotta K, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, Bessho A, Maeda T, Moritaka T, Shibayama T (2005) Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 11(5):417–424

    Article  PubMed  CAS  Google Scholar 

  8. Hotta K, Kiura K, Takigawa N, Yoshioka H, Harita S, Kuyama S, Yonei T, Fujiwara K, Maeda T, Aoe K, Ueoka H, Kamei H, Umemura S, Moritaka T, Segawa Y, Kawai H, Bessho A, Kato K, Tabata M, Tanimoto M (2010) Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group Experience. J Thorac Oncol 5(2):179–184

    Article  PubMed  Google Scholar 

  9. Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T (2004) Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 45(1):93–104

    Article  PubMed  Google Scholar 

  10. Seto T, Yamamoto N (2004) Interstitial lung diseases (ILD) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC): results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey. In: ASCO Annual Meeting Proceedings (Post-Meeting Edition), J Clin Oncol vol 22, no 14S, p 7064, July 15 2004

  11. Chou C, Ko H, Wang C, Yu C, Kuo H, Huang C (2010) Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma. Chang Gung Med J 33(1):100–105

    PubMed  Google Scholar 

  12. Vahid B, Esmaili A (2007) Erlotinib-associated acute pneumonitis: report of two cases. Can Respir J J Can Thorac Soc 14(3):167–170

    Google Scholar 

  13. Del Castillo Y, Espinosa P, Bodi F, Alcega R, Munoz E, Rabasso C, Castander D (2010) Interstitial lung disease associated to erlotinib treatment: a case report. Cases J 3:59

    Article  PubMed  Google Scholar 

  14. Tsujino K, Kawaguchi T, Kubo A, Aono N, Nakao K, Koh Y, Tachibana K, Isa S, Takada M, Kurata T (2009) Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 4(8):994–1001

    Article  PubMed  Google Scholar 

  15. Ratain M, Eckhardt S (2004) Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 22(22):4442–4445

    Article  PubMed  Google Scholar 

  16. Vahid B, Marik P (2008) Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133(2):528–538

    Article  PubMed  CAS  Google Scholar 

  17. Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 91:S18–S23

    Article  PubMed  CAS  Google Scholar 

  18. Muller N, White D, Jiang H, Gemma A (2004) Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 91:S24–S30

    Article  PubMed  Google Scholar 

  19. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R (2003) FDA drug approval summary: Gefitinib (ZD1839)(Iressa (R)) tablets. Oncologist 8(4):303–306

    Article  PubMed  CAS  Google Scholar 

  20. Aoe K, Hiraki A, Murakami T, Maeda T, Umemori Y, Katayama H, Eda R, Takeyama H (2005) Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy. Anticancer Res 25(1B):415–418

    PubMed  Google Scholar 

  21. Endo M, Johkoh T, Kimura K, Yamamoto N (2006) Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 52(2):135–140

    Article  PubMed  Google Scholar 

  22. Um S, Lee S, Yang D, Son C, Roh M, Kim K, Lee K, Choi P (2009) Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis. Clin Respir J 3(3):181–184

    Article  PubMed  CAS  Google Scholar 

  23. Nagaria N, Cogswell J, Choe J, Kasimis B (2005) Side effects and good effects from new chemotherapeutic agents: case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol 23(10):2423–2424

    Article  PubMed  Google Scholar 

  24. Nakagawa M, Teramukai S, Tada H (2005) Hypoalbumia as a risk factor of interstitinal lung disease (ILD) during gefitinib treatment in patients with non-small cell lung cancer (NSCLC): a JMTO study. Proc ASCO 23:667s (Abstract# 7190)

    Google Scholar 

  25. Cohen M, Williams G, Sridhara R, Chen G, McGuinn W, Morse D, Abraham S, Rahman A, Liang C, Lostritto R (2004) United States food and drug administration drug approval summary. Clin Cancer Res 10(4):1212–1218

    Article  PubMed  CAS  Google Scholar 

  26. Cohen M, Johnson J, Chen Y, Sridhara R, Pazdur R (2005) (Tarceva (R)) tablets. Oncologist 10(7):461–466

    Article  PubMed  CAS  Google Scholar 

  27. Herbst R, Prager D, Hermann R, Fehrenbacher L, Johnson B, Sandler A, Kris M, Tran H, Klein P, Li X (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23(25):5892–5899

    Article  PubMed  CAS  Google Scholar 

  28. Gemma A (2009) Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents. J Nippon Med School 76(1):4–8

    Article  Google Scholar 

  29. Dempke WC, Suto T, Reck M (2010) Targeted therapies for non-small cell lung cancer. Lung Cancer 67(3):257–274

    Article  PubMed  Google Scholar 

  30. Wheatley-Price P, Shepherd F (2008) Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol 3(10):1173–1184

    Article  PubMed  Google Scholar 

  31. Ide S, Soda H, Hakariya T, Takemoto S, Ishimoto H, Tomari S, Sawai T, Nagashima S, Furukawa M, Nakamura Y (2010) Interstitial pneumonia probably associated with sorafenib treatment: an alert of an adverse event. Lung Cancer 67(2):248–250

    Article  PubMed  Google Scholar 

  32. Keogh BA, Crystal RG (1982) Alveolitis: the key to the interstitial lung disorders. Thorax 37(1):1–10

    Article  PubMed  CAS  Google Scholar 

  33. Selman M, King TE, Pardo A (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134(2):136–151

    PubMed  CAS  Google Scholar 

  34. Suzuki H, Aoshiba K, Yokohori N, Nagai A (2003) Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 63(16):5054–5059

    PubMed  CAS  Google Scholar 

  35. Higenbottam T, Kuwano K, Nemery B, Fujita Y (2004) Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer 91:S31–S37

    Article  PubMed  CAS  Google Scholar 

  36. Kuwano K, Hagimoto N, Maeyama T, Fujita M, Yoshimi M, Inoshima I, Nakashima N, Hamada N, Watanabe K, Hara N (2002) Mitochondria-mediated apoptosis of lung epithelial cells in idiopathic interstitial pneumonias. Lab Invest 82(12):1695–1706

    PubMed  CAS  Google Scholar 

  37. Aida S, Tamai S, Sekiguchi S, Shimizu N (1994) Distribution of epidermal growth factor and epidermal growth factor receptor in human lung: immunohistochemical and immunoelectron-microscopic studies. Respiration 61(3):161–166

    Article  PubMed  CAS  Google Scholar 

  38. Ryu J (2010) Chemotherapy-induced pulmonary toxicity in lung cancer patients. J Thorac Oncol 5(9):1313–1314

    Article  PubMed  Google Scholar 

  39. Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC (2000) Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 20(5):1245–1259

    PubMed  CAS  Google Scholar 

  40. Tagliabue M, Casella T, Zincone G, Fumagalli R, Salvini E (1994) CT and chest radiography in the evaluation of adult respiratory distress syndrome. Acta Radiol 35(3):230–234

    PubMed  CAS  Google Scholar 

  41. Hansell D, Bankier A, MacMahon H, McLoud T, Muller N, Remy J (2008) Fleischner society: glossary of terms for thoracic imaging1. Radiology 246(3):697–722

    Article  PubMed  Google Scholar 

  42. Lynch D, Travis W, Muller N, Galvin J, Hansell D, Grenier P, King T Jr (2005) Idiopathic interstitial pneumonias: CT features1. Radiology 236(1):10–21

    Article  PubMed  Google Scholar 

  43. Ryu J, Myers J, Swensen S (2003) Bronchiolar disorders. Am J Respir Crit Care Med 168(11):1277–1292

    Article  PubMed  Google Scholar 

  44. Visscher DW, Myers JL (2006) Bronchiolitis: the pathologist’s perspective. Proc Am Thorac Soc 3(1):41–47

    Article  PubMed  Google Scholar 

  45. Dodd J, Lee K, Johkoh T, Muller N (2006) Drug-associated organizing pneumonia: high-resolution CT findings in 9 patients. J Thorac Imaging 21(1):22–26

    Article  PubMed  Google Scholar 

  46. Isabela C, Silva S, Muller N (2006) Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations. Semin Ultrasound CT MR 27(2):111–116

    Article  Google Scholar 

  47. Katzenstein A, Myers J (1998) Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med 157(4):1301–1315

    PubMed  CAS  Google Scholar 

  48. Muller N, Fraser R, Lee K, Johkoh T (2003) Diseases of the lung: radiologic and pathologic correlations. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  49. Yoh K, Kenmotsu H, Yamaguchi Y, Kubota K, Ohmatsu H, Goto K, Niho S, Ohe Y, Saijo N, Nishiwaki Y (2010) Severe interstitial lung disease associated with amrubicin treatment. J Thorac Oncol 5(9):1435–1438

    Article  PubMed  Google Scholar 

  50. Yoneda KY, Shelton DK, Beckett LA, Gandara DR (2007) Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol 2(6):537–543

    Article  PubMed  Google Scholar 

  51. Park S, Kim A, Park J, Shin C, Nam H, Kim L, Cho J, Ryu J, Kwak S (2009) Recurrent erlotinib-induced interstitial lung disease on non-small cell lung cancer. Tuberc Respir Dis 67(5):445–448

    Article  Google Scholar 

Download references

Conflict of interest

The authors have no conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Deparment of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Ji Hye Min, Ho Yun Lee & Kyung Soo Lee

  2. The Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Hoyeong Lim, Myung-Ju Ahn & Keunchil Park

  3. Division of Respiratory and Critical Care Medicine at the Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Man Pyo Chung

Authors
  1. Ji Hye Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ho Yun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hoyeong Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Myung-Ju Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keunchil Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Man Pyo Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kyung Soo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ho Yun Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Min, J.H., Lee, H.Y., Lim, H. et al. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol 68, 1099–1109 (2011). https://doi.org/10.1007/s00280-011-1737-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1737-2

Keywords

Search

Navigation